Grantham, Mayo, Van Otterloo & Co (GMO)
NBIX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Neurocrine Biosciences NBIX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
72,430
+36,804
+103% +$5.46M 0.03% 238
2026
Q1 		$4.69M Buy
35,626
+28,493
+399% +$3.78M 0.01% 334
2025
Q4 		$1.01M Buy
+7,133
New +$1.03M ﹤0.01% 517

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s NBIX Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its Neurocrine Biosciences (NBIX) stake by 103% in Q2 2026, buying an estimated $5.46M and bringing the position to 72,430 shares worth $12.2M. The position accounts for 0.03% of the portfolio, ranked #238.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 72,430 shares of Neurocrine Biosciences worth $12.2M as of Q2 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) bought 36,804 Neurocrine Biosciences shares in Q2 2026, an estimated $5.46M.
  • Neurocrine Biosciences made up 0.03% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #238 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.